Cingulate Inc
CING
查看详细走势图
3.970USD
+0.110+2.85%
收盘 12/19, 16:00（美东）报价延迟15分钟
23.73M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.85%
5天
-10.59%
1月
+14.74%
6月
-4.11%
今年开始到现在
-19.47%
1年
-3.17%
查看详细走势图
TradingKey Cingulate Inc股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值低估，机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
Cingulate Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
3
位分析师
买入
评级
27.400
目标均价
+598.98%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Cingulate Inc亮点
亮点风险
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Cingulate Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Cingulate Inc简介
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
公司代码CING
公司Cingulate Inc
CEOCallahan (Jennifer L)
网址https://www.cingulate.com/
常见问题
Cingulate Inc(CING)的当前股价是多少？
Cingulate Inc(CING)的当前股价是 3.970。
Cingulate Inc的股票代码是什么？
Cingulate Inc的股票代码是CING。
Cingulate Inc股票的52周最高点是多少？
Cingulate Inc股票的52周最高点是6.010。
Cingulate Inc股票的52周最低点是多少？
Cingulate Inc股票的52周最低点是3.200。
Cingulate Inc的市值是多少？
Cingulate Inc的市值是23.73M。
Cingulate Inc的净利润是多少？
Cingulate Inc的净利润为-15.55M。
现在Cingulate Inc(CING)的股票是买入、持有还是卖出？
根据分析师评级，Cingulate Inc(CING)的总体评级为买入，目标价格为27.400。
Cingulate Inc(CING)股票的每股收益（EPS TTM）是多少
Cingulate Inc(CING)股票的每股收益（EPS TTM）是-2.760。
相关品种
